Key facts
- This page summarizes Sanjeev Narula's Form 3 filing for Phathom Pharmaceuticals, Inc. (PHAT).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Oct 2025, 17:22.
Sanjeev Narula - 06 Oct 2025 Form 3 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)
- Reporting relationship
- Chief Financial & Bus. Officer
- Issuer ticker
- PHAT
- Reported as of
- 06 Oct 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 07 Oct 2025, 17:22:26 UTC
- Prior SEC filing
- 02 Apr 2025
- Next SEC filing
- 02 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Anne Marie Cook, Attorney-in-Fact for Sanjeev Narula
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sanjeev Narula filed Form 3 for Phathom Pharmaceuticals, Inc. (PHAT) on 07 Oct 2025.
Change
- Previous filing in this sequence was filed on 02 Apr 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001820590
Primary reporting owner
Narula Sanjeev
- Relationship
- Chief Financial & Bus. Officer
- Address
- C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK
- Signature
- /s/ Anne Marie Cook, Attorney-in-Fact for Sanjeev Narula
- Signature date
- 07 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHAT
holding
No securities are beneficially owned.
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 06 Oct 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.